Actively Recruiting
Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
Led by Keymed Biosciences Co.Ltd · Updated on 2024-10-15
70
Participants Needed
1
Research Sites
216 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a multicenter, randomized phase II clinical study to evaluate Efficacy and safety, while observing pharmacokinetic profiles, pharmacodynamic effects, and immunogenicity of CM338 in subjects with Immunoglobulin A(IgA) nephropathy.
CONDITIONS
Official Title
Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18-75.
- Understand the nature of the study and sign the Informed Consent Form voluntarily.
- Take effective contraception measures throughout the study period.
You will not qualify if you...
- Used other investigational drugs within 30 days before the first study administration.
- Previous history of Human immunodeficiency virus (HIV) infection.
- Treponema pallidum antibody positive in screening period.
- May have active Mycobacterium tuberculosis infection.
- Major surgery is planned during the study.
- Other reasons the investigator believes that the subject is not suitable to participate in this study.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University First Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
Research Team
Q
Qian Jia
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here